A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial Comparing Two Doses of VF001-DP to Placebo as an Adjunct to Standard Care in Patients With Chronic Venous Leg Ulcers
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2017
At a glance
- Drugs VF 001 (Primary)
- Indications Varicose ulcer
- Focus Therapeutic Use
- Sponsors Factor Therapeutics
- 30 Nov 2017 Planned End Date changed from 1 Nov 2017 to 1 Nov 2018.
- 30 Nov 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Aug 2018.
- 05 Oct 2017 According to a Factor Therapeutics media release, the company has added four new sites into the trial, one in California, one in Florida and two in Puerto Rico.